{"protocolSection":{"identificationModule":{"nctId":"NCT05151874","orgStudyIdInfo":{"id":"IIBSP-ROM-2020-135"},"organization":{"fullName":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","class":"OTHER"},"briefTitle":"Valuation of the Evolution of Passive Mobility in the Spastic Upper Limb After Injection of Abobotulinumtoxin(Dysport®)","officialTitle":"Valuation of the Evolution of Passive Mobility (ROM)in the Spastic Upper Limb After Injection of Abobotulinumtoxin(Dysport®) in Patients With Post-stroke Spasticity","acronym":"ROM-ICTUS"},"statusModule":{"statusVerifiedDate":"2021-11","overallStatus":"UNKNOWN","lastKnownStatus":"NOT_YET_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2022-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2022-12","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-08-06","studyFirstSubmitQcDate":"2021-11-26","studyFirstPostDateStruct":{"date":"2021-12-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2021-11-26","lastUpdatePostDateStruct":{"date":"2021-12-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","class":"OTHER"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"Assessing the objective measurement of passive joint mobility (ROM) in the spastic upper limb with Jost's pattern III in patients with post-stroke spasticity after infiltration with BoNT-A allows to objectify the increase in passive joint balance (ROM).","detailedDescription":"Changes in joint mobility in patients with post-stroke upper limb spasticity after infiltration of botulinum toxin type A.\n\nThe spasticity pattern that will be evaluated will be pattern number III based on the classification of Jost et al. Joint mobility will be measured with the Lynx instrument (DyCare)"},"conditionsModule":{"conditions":["Spasticity, Muscle","Stroke Sequelae","Movement Disorders"],"keywords":["Spasticity","Abobotulinum toxin","Injection","Rehabilitation"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"CASE_ONLY","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":12,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Range of movement","description":"Change in passive joint mobility (ROM) of the carpus (flexion-extension) affected by spasticity pattern III during a 20-week follow-up.","interventionNames":["Drug: Abobotulinum toxin A"]}],"interventions":[{"type":"DRUG","name":"Abobotulinum toxin A","description":"To measure ROM evolution in patients with post-stroke spasticity in the upper limb with spasticity pattern III.","armGroupLabels":["Range of movement"],"otherNames":["toxin infiltration"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in passive range of motion","description":"Change in passive joint mobility (ROM) of the upper limb affected by spasticity pattern III a 20-week follow-up.","timeFrame":"Through study completion, an average of 1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients aged ≥ 18 years.\n* Hemiplegic patients with post-stroke upper limb spasticity affected by pattern III1 who have undergone at least 2 cycles of previous treatment with BoNT-A\n* Patients with a MAS scale (Modified Ashworth Scale) between 2 and 3 for the affected muscle group; shoulder, elbow, carpus and metacarpophalangeal.\n* Patients with Hackett ultrasound qualitative scale between 2 and 3 for the affected muscle group; shoulder, elbow, carpus and metacarpophalangeal.\n\nExclusion Criteria:\n\n* Patients who do not wish to sign the informed consent.\n* Prior lack of primary or secondary response to any BoNT-A for any specific condition or known sensitivity to BoNT-A or any excipient.\n* Routine or prescribed treatment with any medication that directly or indirectly interferes with neuromuscular function in the last 3 months prior to study botulinum toxin treatment.\n* Having undergone surgery on the muscles, ligaments, tendons, nerves or bones of the limb to be treated.\n* Any medical condition or analytical finding that, in the opinion of the investigator, may compromise compliance with the objectives and / or procedures of the study protocol or exclude the administration of BoNT-A.\n* Treatment with an investigational new drug in the 4 weeks or 5 half-lives prior to screening to enter the study.\n* Pregnancy.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"99 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients aged ≥ 18 years.\n\nHemiplegic patients with post-stroke upper limb spasticity affected by pattern III1 who have undergone at least 2 cycles of previous treatment with BoNT-A\n\nPatients with a MAS scale (Modified Ashworth Scale) between 2 and 3 for the affected muscle group; shoulder, elbow, carpus and metacarpophalangeal.\n\nPatients with Hackett ultrasound qualitative scale between 2 and 3 for the affected muscle group; shoulder, elbow, carpus and metacarpophalangeal.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"locations":[{"facility":"Hospital de la Santa Creu i Sant Pau","city":"Barcelona","zip":"08041","country":"Spain","contacts":[{"name":"Helena Bascuñana, Dr","role":"CONTACT","phone":"+34 935537059","email":"hbascunana@santpau.cat"},{"name":"Eliot Ramirez, Dr","role":"CONTACT","phone":"+34 935537059","email":"eramirezm@santpau.cat"}],"geoPoint":{"lat":41.38879,"lon":2.15899}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000009128","term":"Muscle Spasticity"},{"id":"D000009069","term":"Movement Disorders"}],"ancestors":[{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000009135","term":"Muscular Diseases"},{"id":"D000009140","term":"Musculoskeletal Diseases"},{"id":"D000009122","term":"Muscle Hypertonia"},{"id":"D000020879","term":"Neuromuscular Manifestations"},{"id":"D000009461","term":"Neurologic Manifestations"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M11719","name":"Movement Disorders","asFound":"Movement Disorders","relevance":"HIGH"},{"id":"M11775","name":"Muscle Spasticity","asFound":"Spasticity","relevance":"HIGH"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M11782","name":"Muscular Diseases","relevance":"LOW"},{"id":"M11787","name":"Musculoskeletal Diseases","relevance":"LOW"},{"id":"M11769","name":"Muscle Hypertonia","relevance":"LOW"},{"id":"M22309","name":"Neuromuscular Manifestations","relevance":"LOW"},{"id":"M12094","name":"Neurologic Manifestations","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC05","name":"Musculoskeletal Diseases"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"C000542869","term":"abobotulinumtoxinA"},{"id":"D000019274","term":"Botulinum Toxins, Type A"}],"ancestors":[{"id":"D000065087","term":"Acetylcholine Release Inhibitors"},{"id":"D000049990","term":"Membrane Transport Modulators"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000018678","term":"Cholinergic Agents"},{"id":"D000018377","term":"Neurotransmitter Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"},{"id":"D000009465","term":"Neuromuscular Agents"},{"id":"D000018373","term":"Peripheral Nervous System Agents"}],"browseLeaves":[{"id":"M250157","name":"abobotulinumtoxinA","asFound":"Nerve plexus","relevance":"HIGH"},{"id":"M20947","name":"Botulinum Toxins, Type A","asFound":"Nerve plexus","relevance":"HIGH"},{"id":"M4873","name":"Botulinum Toxins","relevance":"LOW"},{"id":"M3163","name":"Acetylcholine","relevance":"LOW"},{"id":"M20448","name":"Cholinergic Agents","relevance":"LOW"},{"id":"M20194","name":"Neurotransmitter Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"VaDiAg","name":"Vasodilator Agents"}]}},"hasResults":false}